CTI Molecular Imaging subsidiary PETNET Solutions has struck a deal to provide PET isotopes to a GlaxoSmithKline research site. The isotopes will be used for preclinical research. PETNET will have the option, at GSK's discretion, to license diagnostic
CTI Molecular Imaging subsidiary PETNET Solutions has struck a deal to provide PET isotopes to a GlaxoSmithKline research site. The isotopes will be used for preclinical research. PETNET will have the option, at GSK's discretion, to license diagnostic PET probes developed by GSK. The partnership is in line with PETNET's strategy to develop new proprietary probes that will augment its existing R&D pipeline.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.